S.A. Mason LLC Decreases Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

S.A. Mason LLC cut its stake in Illumina, Inc. (NASDAQ:ILMN) by 7.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,770 shares of the life sciences company’s stock after selling 150 shares during the period. S.A. Mason LLC’s holdings in Illumina were worth $246,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Brown Brothers Harriman & Co. grew its holdings in Illumina by 460.9% in the 1st quarter. Brown Brothers Harriman & Co. now owns 129 shares of the life sciences company’s stock valued at $45,000 after buying an additional 106 shares in the last quarter. State of Wyoming purchased a new stake in shares of Illumina in the second quarter valued at about $32,000. Penserra Capital Management LLC acquired a new stake in Illumina during the first quarter worth about $64,000. ST Germain D J Co. Inc. purchased a new position in Illumina during the second quarter worth about $36,000. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Illumina in the 3rd quarter valued at about $30,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Insider Activity at Illumina

In other news, CEO Jacob Thaysen purchased 7,330 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares in the company, valued at approximately $2,010,544.69. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ILMN shares. TD Cowen lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 price target on the stock. in a research report on Thursday, January 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $258.00 price target on shares of Illumina in a research note on Friday, February 9th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Stephens reaffirmed an “overweight” rating and set a $170.00 target price on shares of Illumina in a research note on Wednesday, February 14th. Finally, Guggenheim initiated coverage on shares of Illumina in a report on Thursday, December 14th. They issued a “buy” rating and a $155.00 price objective on the stock. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $166.95.

Illumina Trading Up 3.6 %

Shares of ILMN stock opened at $138.68 on Thursday. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $233.42. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26. The firm has a fifty day moving average price of $138.29 and a 200 day moving average price of $129.31.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the prior year, the company posted $0.14 earnings per share. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. As a group, sell-side analysts expect that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.